CTOs on the Move

Umoja Biopharma

www.umoja-biopharma.com

 
Umoja is developing a new approach to cancer therapy that retools a patient`s immune system in vivo, enhancing the body`s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Umoja Biopharma raised $53M on 11/18/2020
Umoja Biopharma raised $210M on 06/15/2021

Similar Companies

RTI Surgical®

RTI Surgical (RTI) is a global, industry leading surgical implant supplier that provides design, new product development, processing and manufacturing services in support of patients and leading medical technology companies. With expertise spanning tis...

Biorasi

Biorasi is an award-winning full service, global Clinical Research Optimized (CRO). From project design to execution success, optimization is engrained in ProAct+. An integrated platform of high performance systems, tools, and processes. By developing and implementing groundbreaking methods of optimizing clinical research, we contribute to enhancement of health and well-being for people around the world.    Powered by ProAct+, Biorasi`s full service project teams have developed numerous drugs, biologics and devices that received FDA and multi-venue approvals. Biorasi is headquartered in Miami, FL and has regional operations around the world.

Cardior Pharmaceuticals

Pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart.

Apple Discount Drugs

Apple Discount Drugs is a Salisbury, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Servier Pharmaceuticals

Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients` lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes.